pSTAT1 is not a favorable prognostic indicator in HNSCC patients treated with adjuvant cisplatin and panitumumab. Tumor specimens from patients with advanced, high risk HNSCC were collected prior to adjuvant radiation, cisplatin, and panitumumab, then stained for p-S727-STAT1 (A) and p-Y701-STAT1 (B). Patients were divided into high or low phospho-STAT1 groups (above or below mean), and survival was assessed.